Thomas Jefferson University

Program Directors

Thomas Jefferson University

Scott A. Waldman, MD, PhD, FCP, FAHA. Dr. Waldman received his PhD in Anatomy, from Thomas Jefferson University in ‘80. Subsequently, he pursued a postdoctoral fellowship in clinical pharmacology under the supervision of the Nobel Laureate Ferid Murad, MD, PhD at the University of Virginia, Charlottesville (‘79-‘81) and Stanford University, Palo Alto (‘81-‘83). In ‘83, he completed a fellowship program in the Division of Clinical Pharmacology at Stanford University. He obtained his MD in ‘87 and completed his training in Internal Medicine in ‘90 at Stanford University. In ‘90, he joined the faculty of Thomas Jefferson University where he is the Samuel MV Hamilton Professor and Chair of the Department of Pharmacology and Experimental Therapeutics. Dr. Waldman has received numerous honors and awards including the Henry Elliott (2010) and Rawls Palmer Progress in Medicine (2012) Awards from the American Society for Clinical Pharmacology and Therapeutics, the Pharmaceutical Manufacturers Association Foundation Award in Excellence in Clinical Pharmacology (2011), and the George Kolle Award from the Mid-Atlantic Pharmacology Society (2103). He has had significant leadership roles in pharmacology professional societies, President of the American Society for Clinical Pharmacology and Therapeutics, (’01-‘02), an elected Regent of the American College of Clinical Pharmacology (’99-’04), a member of the American Board of Clinical Pharmacology (’99-’04), and most recently Chair of the Scientific Program Committee for the American Society for Pharmacology and Experimental Therapeutics (2011-present). He is a Fellow of the American College of Clinical Pharmacology (FCP) and the American Heart Association (FAHA). He is the Editor-In-Chief of Clinical Pharmacology and Therapeutics, the top research journal in pharmacology. Also, he is the Founder of the journals Biomarkers In Medicine, and Clinical and Translational Science. Moreover, he is Co-Editor of the textbook Pharmacology And Therapeutics: Principles To Practice (2009). Dr. Waldman’s research activities focus on human clinical pharmacology and drug development, molecular mechanisms underlying tissue organization and tumorigenesis, and novel approaches to the diagnosis and treatment of cancer. His work can be viewed at: ?sort=date&direction=ascending

Walter K. Kraft, MD, MS, FACP. Dr. Kraft, the 5th fellow supported by this training grant, serves as a Program Co-Director. Following a two-year fellowship supported by this training grant, he joined the (’01). Dr. Kraft presently serves as the Director of the Clinical Research Unit in the Department of Pharmacology and Experimental Therapeutics, with secondary appointments at the professor rank in the Departments of Surgery and Medicine. His research interests focus on the treatment of the neonatal abstinence syndrome and on phase I clinical trials. He is directly responsible for ~$2.5 million/year in grant funding, with an emphasis in first-in-human, early phase clinical and experimental medicine trials in both healthy volunteers and special populations. He maintains a clinical practice in hospital-based vascular medicine.

Dr. Kraft is Director of the Office of Human Research, which oversees the Thomas Jefferson University Institutional Review Boards. He is treasurer of the American Society and Clinical Pharmacology and Therapeutics, and previously sat on the governing board of the American Board of Clinical Pharmacology (‘07-‘12) and Association of Clinical Pharmacology Units (‘10-‘12). He has chaired Program Committee for national scientific meetings and has served on a number of NIH ad hoc (XNDA) and special emphasis panels, particularly those in pediatric pharmacology. He has been involved in international efforts to standardize neonatal pharmacology research and to combat child drug abuse. He was awarded the Jefferson Medical College Early Career Investigator Award for Distinguished Achievement in Biomedical Research (’11), and Deans Award for Excellence in Teaching (’14). In 2010 he founded the Jefferson College within the College, a medical school track specifically designed to foster research in undergraduate medical students. The program has enrolled >180 medical students. He also directs the Training Program in Human Investigation and has formally mentored 35 Masters and PhD students and 29 fellows in this program. His work can be viewed at:


Children’s Hospital of Philadelphia (CHOP)

Peter Adamson, MD. Dr. Adamson is Professor of Pediatrics and Pharmacology at the University of Pennsylvania and Chief of the Division of Clinical Pharmacology and Therapeutics at CHOP. In January ‘11 he became Chair of the Children’s Oncology Group, an NCI-supported global consortium of more than 220 centers which conducts clinical-translational research and large-scale clinical trials in children with cancer. Dr. Adamson is Board Certified in Pediatric Hematology/Oncology and in Clinical Pharmacology. He is an internationally recognized leader in pediatric cancer drug development, serving until 2008 as Chair of the Children’s Oncology Group’s Developmental Therapeutics Program. Prior to becoming Chair of the Children’s Oncology Group, he was Director for Clinical and Translational Research at CHOP, including being the co-Director of the University of Pennsylvania–CHOP Clinical Translational Science Award (CTSA), Director of the CHOP Pediatric General Clinical Research Center, and Principal Investigator of CHOP’s NICHD-funded Pediatric Pharmacology Research Unit. His laboratory focuses on the clinical pharmacology of drugs for childhood cancer using an integrated approach incorporating preclinical model systems and clinical trials with pharmacokinetic-pharmacodynamic-pharmacogenetic studies.

Athena Zuppa MD MSCE, FAAP, FCP. Dr. Zuppa completed residency training in pediatrics and fellowship training in pediatric critical care medicine at CHOP. Following her appointment to Assistant Professor in 2002 she devoted significant effort to clinical service in the pediatric intensive care unit, and was awarded the Residency Teaching Award from CHOP in 2004 and the Honoring Excellence, Best Leader of Family-Centered Care Award in 2006. She received a Master’s of Science in Clinical Epidemiology from the University of Pennsylvania in June 2004. In 2002, she received a Mentored Specialized Clinical Investigator Development Award from the National Institutes of Child Health and Development Pediatric Pharmacology Research Unit.  In 2004 she was awarded a K23 grant entitled Improving Drug Development for the Critically Ill Child, sponsored though the NICHD.  During this time she focused her training on pharmacometrics. In 2009 she received an R01 entitled The Impact of Pharmacology on Sedation Assessments in Children who are Mechanically Ventilated, sponsored through the NIH’s Heart, Lung and Blood Institute (NHLBI). In 2012 she received an additional R01 through the NHLBI entitled Hypothermia’s Impact on Pharmacology. Further, she serves as the Co-Principal Investigator for CHOP’s participation in the NICHD sponsored Collaborative Pediatric Critical Care Network. Nationally, she served as a voting member of the FDA Anesthesia and Life Support Medications Subcommittee. She was elected to the Board of Regents of the American College of Clinical Pharmacology in 2006 and served for two years.  She is an Associate Director of the Pediatric Critical Care fellowship program, and is primarily responsible for mentoring all fellows throughout their research experience regardless of the projects. She has developed a core research curriculum for the fellows based on the recommendations of the American Board of Pediatrics. Her work can be viewed at: